University of Miami's 2nd Biennial Miami Leukemia Symposium

 

University of Miami's 2nd Biennial Miami Leukemia Symposium
Avatar

Venetoclax Can Effectively Target AML Stem Cells Through Acid-Fueled OXPHOS, AML M5 Is a Risk Factor for Lack of Response to Venetoclax

By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Daniel Pollyea
By University of Miami's 2nd Biennial Miami Leukemia Symposium FEATURING Daniel Pollyea
23 views
May 14, 2020
0 Comments
Login to view comments. Click here to Login

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay
AML Biology and Treatment
20:35
University of Miami's 2nd Biennial Miami Leukemia Symposium

Curing APL in 2020: Have We Completely Deciphered Mechanism(s) of Co…

Feat. M. Tallman
16:42
University of Miami's 2nd Biennial Miami Leukemia Symposium

IDH Inhibitors in Myeloid Malignancies: What Are the Mechanisms of R…

Feat. E. Stein
20:28
University of Miami's 2nd Biennial Miami Leukemia Symposium

Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding A…

Feat. M. Guzman
23:05
University of Miami's 2nd Biennial Miami Leukemia Symposium

Venetoclax Can Effectively Target AML Stem Cells Through Acid-Fueled…

Feat. D. Pollyea